Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyureaAbdulraheem Yacoub, Ronald Hoffman, John Mascarenhas et al.|Blood|2019Cited by 175
Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN StudyAjay K. Gopal, Gilles Salles, Stephen J. Schuster et al.|Journal of Clinical Oncology|2018Cited by 103
Ruxolitinib Therapy Followed by Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation for Myelofibrosis: Myeloproliferative Disorders Research Consortium 114 StudyVikas Gupta, Ronald Hoffman, Heidi Kosiorek et al.|Transplantation and Cellular Therapy|2018Cited by 59
Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)John Mascarenhas, Robert S. Hoffman, Mary Frances McMullin et al.|Blood|2018Cited by 45
A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with MyelofibrosisJohn Mascarenhas, Ronald Hoffman, Anna Ritá Migliaccio et al.|Clinical Cancer Research|2023Cited by 34